Enjoy Good Food: Førsteklasses europeiske frukt- og grønnsaker spiller en viktig rolle i den norske sommeren
Prosjektet «Euphoria – Europeisk produksjon av frukt og grønnsaker: en garanti for kvalitet og velvære», opprettet med bidrag fra EU, tar sikte på å promotere frukt og grønnsaker fra EU der sluttforbrukeren faktisk befinner seg, og nå er prosjektet klart for Norge.
Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20210721005862/no/
Søndag 27. juni 2021 starter et aktivitetsprogram som vil involvere Oslo by og dens innbyggere gjennom hele sommeren.
Frem til søndag 8. august vil tre utsalgssteder som er kjent for norske forbrukere, være vertskap for markedsførings- og informasjonsaktivitetene, som inkluderer smaksprøver og informasjonskampanjer.
Euphoria-prosjektet har en total varighet på tre år og involverer, i tillegg til det norske markedet, også det sveitsiske. Prosjektet består av en rekke initiativer og integrerte kommunikasjonsaktiviteter rettet mot å lære forbrukere og bransjeoperatører om kvaliteter og egenskaper ved europeisk frukt og grønnsaker.
Kampanjen «i butikk» som er planlagt til sommeren, vil gå over totalt 84 dager og involvere to butikker i Smak AV Italia-kjeden og Mathallen i Oslo.
Forbrukerne som deltar kommer til å møte, i hjørnene som er satt opp innenfor disse tre salgsstedene, opplært personell som kan gi dem all nyttig informasjon om europeisk frukt og grønnsaker. De vil motta informasjonsmateriell om prosjektet, vil få muligheten til å smake noen av disse delikatessene og hvis de ønsker det, kan de prøve seg på en av oppskriftene som er foreslått i kokeboken, utviklet i samarbeid med Iside De Cesare, 1* Michelin-kokk.
Blant produktene som forbrukerne finner som smaksprøver er melon, forfriskende, lite kalorier, rik på mineraler og vitaminer, en gyldig alliert for slå sommervarmen og for et sunt og kalorifattig kosthold, og vannmelon, rik på gunstige egenskaper for kroppen, som takket være det høye vanninnholdet (opptil 95 %) hjelper til med å gjeninnføre væskebalansen som går tapt på grunn av sommervarmen.
Listen over kampanjedager og salgssteder er tilgjengelig på nettsiden https://enjoygoodfood.eu/
Følg prosjektet videre:
Facebook: https://www.facebook.com/Enjoy-Good-Food-109095297657079/
Instagram: https://www.instagram.com/enjoygoodfood.eu/
Hvis du vil se dette innholdet fra cts.businesswire.com, gi ditt samtykke øverst på denne siden.
https://www.businesswire.com/news/home/20210721005862/no/
Contact information
Roberto D’Amico
info@enjoygoodfood.eu
Om Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg pressemeldinger fra Business Wire
Registrer deg med din e-postadresse under for å få de nyeste sakene fra Business Wire på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com